Transition from generics to biotech — attractive opportunities ahead
Thursday, March 26, 2020
Pharmaceutical companies in Asia have scaled up over the past two decades to emerge as key manufacturing hubs for the requirements of the western world. As these companies from China, India, Korea and Taiwan transition from generics manufacturing to high-end research, interesting opportunities are emerging for long-term investors. Attend this panel discussion to analyse key trends in biotech research and evaluate long-term ideas.